Lexaria Bioscience (LEXX) to Release Quarterly Earnings on Friday

Lexaria Bioscience (NASDAQ:LEXX) is expected to release its earnings data before the market opens on Friday, July 11th. Analysts expect Lexaria Bioscience to post earnings of ($0.15) per share and revenue of $0.17 million for the quarter.

Lexaria Bioscience (NASDAQ:LEXX) last announced its earnings results on Monday, April 14th. The company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.01. The business had revenue of $0.17 million for the quarter, compared to the consensus estimate of $0.14 million. Lexaria Bioscience had a negative net margin of 1,784.03% and a negative return on equity of 111.84%. On average, analysts expect Lexaria Bioscience to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Lexaria Bioscience Trading Up 4.7%

Lexaria Bioscience stock opened at $0.90 on Friday. The firm has a 50-day moving average price of $1.02 and a 200-day moving average price of $1.47. The firm has a market capitalization of $15.72 million, a PE ratio of -1.52 and a beta of 0.79. Lexaria Bioscience has a 12-month low of $0.82 and a 12-month high of $4.38.

Analysts Set New Price Targets

Separately, HC Wainwright decreased their price objective on shares of Lexaria Bioscience from $7.00 to $5.00 and set a “buy” rating for the company in a research note on Tuesday.

About Lexaria Bioscience

Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods.